{"version": "https://jsonfeed.org/version/1.1", "title": "Sharemaestro Newsreel: Germany Medical Devices news", "home_page_url": "https://sharemaestro.com/newsreel/de/healthcare/medical-devices/", "feed_url": "https://sharemaestro.com/newsreel/de/healthcare/medical-devices/feed.json", "description": "Latest Medical Devices company headlines from Germany, newest first, with source links and direct routes to company research and sentiment.", "language": "en", "items": [{"id": "source:0255478c1d6a1daa9aacd8e79c7f2c3be6c707552e7a68c1d719ffab92cbcba9", "url": "https://news.google.com/rss/articles/CBMizwFBVV95cUxOUTBrcnB6NEc5S0FXdmF2WHZoa2RMR2lzbS1fOVBTSTVaSGF5ZGJyOVFZT0Q5WFBBRzdHelNKeG1zVmFDekNfaVNfY25kRGxQaUFGUmFzY2dRa3NPcXZzZ05xeFBfd0JCUmxjR213WWY2TEw0U2V5ZWtEOFl1RFZHX3h5WWpNTmV3VUVOYXN2SGs3R24yZmRXOGFJYVZ3MFlSVEhqNVJNTFZOaXBtYnl1QVJnQmxUam5hZWQwa2hyRURwdWJNSFRiWDI1N0l1RGs?oc=5", "external_url": "https://news.google.com/rss/articles/CBMizwFBVV95cUxOUTBrcnB6NEc5S0FXdmF2WHZoa2RMR2lzbS1fOVBTSTVaSGF5ZGJyOVFZT0Q5WFBBRzdHelNKeG1zVmFDekNfaVNfY25kRGxQaUFGUmFzY2dRa3NPcXZzZ05xeFBfd0JCUmxjR213WWY2TEw0U2V5ZWtEOFl1RFZHX3h5WWpNTmV3VUVOYXN2SGs3R24yZmRXOGFJYVZ3MFlSVEhqNVJNTFZOaXBtYnl1QVJnQmxUam5hZWQwa2hyRURwdWJNSFRiWDI1N0l1RGs?oc=5", "title": "Die Edwards-Lifesciences-Aktie steigt dank starker Q2-Dynamik und hoher Bewertung", "content_text": "Die Edwards-Lifesciences-Aktie steigt dank starker Q2-Dynamik und hoher Bewertung", "date_published": "2026-08-14T17:36:18+00:00", "authors": [{"name": "AD HOC NEWS"}], "tags": ["Market update", "EWL"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "EWL", "name": "Edwards Lifesciences Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/d182ff67-5fcd-48c1-9450-8975babb5883/"}]}}, {"id": "source:3d2b95b95e91585aab83cab8182fc725b8b90acb95a0866a27394d1280ac023b", "url": "https://news.google.com/rss/articles/CBMizgFBVV95cUxPMGxSMV9rVGpXTU1SNUdvaUZBdzdjazdQbUJ4aS1yY0Y5OVVmdDRiRlBTZngzR2ZCZ21KS2pKUjdYc0JnSEVuZHZwRGt4VXZyZm9QUUFOaUVxeGpNQzh3d3NKN2x1U0lvMW15YXlSaXkwX1ZlMUNWMUMtNUgzZU43LTRIWWJYRThmSU5TQjBZblduT202OGtONVFOZW5YZjRIcjdRY2NnWElaNTZCWE4zZmN2V202VmREU19sVldlNlJLUTduWHgtV2RCNGhpUQ?oc=5", "external_url": "https://news.google.com/rss/articles/CBMizgFBVV95cUxPMGxSMV9rVGpXTU1SNUdvaUZBdzdjazdQbUJ4aS1yY0Y5OVVmdDRiRlBTZngzR2ZCZ21KS2pKUjdYc0JnSEVuZHZwRGt4VXZyZm9QUUFOaUVxeGpNQzh3d3NKN2x1U0lvMW15YXlSaXkwX1ZlMUNWMUMtNUgzZU43LTRIWWJYRThmSU5TQjBZblduT202OGtONVFOZW5YZjRIcjdRY2NnWElaNTZCWE4zZmN2V202VmREU19sVldlNlJLUTduWHgtV2RCNGhpUQ?oc=5", "title": "Die Abbott-Laboratories-Aktie legt nach starker Q2-Guidance moderat zu", "content_text": "Die Abbott-Laboratories-Aktie legt nach starker Q2-Guidance moderat zu", "date_published": "2026-08-14T15:49:44+00:00", "authors": [{"name": "AD HOC NEWS"}], "tags": ["Market update", "ABL"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ABL", "name": "Abbott Laboratories", "sentiment_url": "https://sharemaestro.com/sentiment/5aee0440-2bab-4e30-b16e-000aa7acbda4/"}]}}, {"id": "source:611c3c7e6d9823abbad41de0d6d89812c8b0824bb262f604ee9ed7202f98c020", "url": "https://finance.yahoo.com/healthcare/articles/boston-scientific-bsx-faces-growth-102442230.html", "external_url": "https://finance.yahoo.com/healthcare/articles/boston-scientific-bsx-faces-growth-102442230.html", "title": "Boston Scientific (BSX) Faces Growth Slowdown in Key Businesses", "content_text": "Parnassus Investments, an investment management company, released the \"Parnassus Core Equity Fund\" second quarter of 2026 investor letter. A copy of the letter can be downloaded here. The fund returned 16.83% in the second quarter of 2026, outperforming the S&P 500's 15.20% gain. Performance was supported by holdings in Information Technology and Communication Services, as well as the fund's lack of Energy exposure, while Financials and Health Care detracted. The fund is positioning for long-term growth through AI infrastructure, semiconductors, electrification and industrial automation, while", "date_published": "2026-08-14T10:24:42+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "BSX"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "BSX", "name": "Boston Scientific Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/e71a4929-5366-46c6-b81d-15099a7fb8e0/"}]}}, {"id": "source:483dae81a8645750f94d73ba0194dddd2330f8746335755914527985d64a5d07", "url": "https://seekingalpha.com/news/4633059-sp500-nasdaq-dow-jones-outlook-stock-market?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "external_url": "https://seekingalpha.com/news/4633059-sp500-nasdaq-dow-jones-outlook-stock-market?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "title": "Stock index futures largely flat after S&P 500 closes at record high", "content_text": "[Wall Street New York stock exchange stock market] alexsl Stock index futures were muted on Friday after the S&P 500 closed at a record high in the previous session. Dow futures (INDU [https://seekingalpha.com/symbol/INDU]) -0.12%, S&P 500 futures (SPX [https://seekingalpha.com/symbol/SPX]) +0.02%, and Nasdaq futures (US100:IND) -0.24%. The S&P 500 reached another intraday record on Thursday as investors weighed July producer prices, which showed wholesale inflation was unchanged from the previous month. Investors will turn to July retail sales data at 8:30 a.m. ET for fresh clues on consumer ", "date_published": "2026-08-14T08:11:29+00:00", "authors": [{"name": "seekingalpha.com"}], "tags": ["Macro sensitivity", "BSX"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "BSX", "name": "Boston Scientific Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/e71a4929-5366-46c6-b81d-15099a7fb8e0/"}]}}, {"id": "source:2119559983d88f54fed2f9b6de7ae9cd6c9c03584d4dbac9d637eb5c0a7d098a", "url": "https://finance.yahoo.com/healthcare/articles/philips-enxtam-phia-expands-open-001645833.html", "external_url": "https://finance.yahoo.com/healthcare/articles/philips-enxtam-phia-expands-open-001645833.html", "title": "Philips (ENXTAM:PHIA) Expands Open Monitoring Ecosystem And Launches Postpartum Support Tool", "content_text": "Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Koninklijke Philips (ENXTAM:PHIA) announces new collaborations to expand its open monitoring ecosystem and connected care offerings. The company introduces the Philips Avent Share the Care Connector to support postpartum mothers with digital tools and guidance. Philips works with health technology partners to extend continuous and out of hospital patient monitoring capabilities. The Share the Care Connector is launched in co", "date_published": "2026-08-14T00:16:45+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Guidance", "PHI1"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "PHI1", "name": "Koninklijke Philips N.V.", "sentiment_url": "https://sharemaestro.com/sentiment/1cc4de78-0344-4bf2-8f9e-a385142353b4/"}]}}, {"id": "source:244e49ff005a068ab08a7c98d6917683f94fa19dc5eb742699689f75b3548f59", "url": "https://finance.yahoo.com/markets/stocks/articles/koninklijke-philips-enxtam-phia-following-171103976.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/koninklijke-philips-enxtam-phia-following-171103976.html", "title": "Koninklijke Philips (ENXTAM:PHIA) Following Exor Stake Update Still Looks Close To Fair Value", "content_text": "Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Koninklijke Philips (ENXTAM:PHIA) has drawn renewed attention after updating its long-term agreement with Exor. The move allows Exor to raise its shareholding to 22%, while existing governance arrangements remain unchanged. See our latest analysis for Koninklijke Philips. At a share price of \u20ac23.19, Koninklijke Philips has seen a small pullback over the past month with a 1 month share price return of a 3.74% decline, although the 3 year total shareholder return of 31.21% points to a stro", "date_published": "2026-08-13T17:11:03+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "PHI1"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "PHI1", "name": "Koninklijke Philips N.V.", "sentiment_url": "https://sharemaestro.com/sentiment/1cc4de78-0344-4bf2-8f9e-a385142353b4/"}]}}, {"id": "source:21cdd6efb4f006a77a1ccec8b3e58b1a3934172bb51c9e54a5a601ca9f190457", "url": "https://finance.yahoo.com/media-advertising/articles/advertising-research-foundation-announces-2026-150200996.html", "external_url": "https://finance.yahoo.com/media-advertising/articles/advertising-research-foundation-announces-2026-150200996.html", "title": "The Advertising Research Foundation Announces 2026 ARF David Ogilvy Awards Finalists", "content_text": "NEW YORK, Aug. 13, 2026 /PRNewswire/ -- The Advertising Research Foundation (ARF) today announced the finalists for the 2026 ARF David Ogilvy Awards, honoring excellence in research-driven advertising and marketing. For more than 30 years, the ARF David Ogilvy Awards have recognized campaigns that demonstrate how consumer insights and research can inspire creative work that delivers measurable business results. This year's finalists represent leading brands across categories including Automotive, B2B, Cultural Fluency, Financial Services & Insurance, Food & Beverage, Health & Personal Care, Be", "date_published": "2026-08-13T15:02:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "ABL"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "ABL", "name": "Abbott Laboratories", "sentiment_url": "https://sharemaestro.com/sentiment/5aee0440-2bab-4e30-b16e-000aa7acbda4/"}]}}, {"id": "source:ee0618ae1b8b072725f1e35425e9f6572cc85101cdb458259b9d8ae643b47603", "url": "https://finance.yahoo.com/markets/stocks/articles/brokers-suggest-investing-boston-scientific-133002959.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/brokers-suggest-investing-boston-scientific-133002959.html", "title": "Brokers Suggest Investing in Boston Scientific (BSX): Read This Before Placing a Bet", "content_text": "When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important? Let's take a look at what these Wall Street heavyweights have to say about Boston Scientific (BSX) before we discuss the reliability of brokerage recommendations and how to use them to your advantage. Boston Scientific currently has an average brokerage recommendation (ABR) of 1.53, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculat", "date_published": "2026-08-13T13:30:02+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Analyst action", "BSX"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "BSX", "name": "Boston Scientific Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/e71a4929-5366-46c6-b81d-15099a7fb8e0/"}]}}, {"id": "source:91875fdb5d67566419d7d4051307e6b3abbebb46420bafca0fa9e12694573ce5", "url": "https://finance.yahoo.com/markets/stocks/articles/hurt-boston-scientific-corporation-bsx-131453714.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/hurt-boston-scientific-corporation-bsx-131453714.html", "title": "Here\u2019s What Hurt Boston Scientific Corporation (BSX) in Q2", "content_text": "TCW Funds, an investment management firm, published its second-quarter 2026 investor letter for the 'TCW Concentrated Large Cap Growth Fund.' A copy of the letter can be downloaded here. During the second quarter, AI monetization, a fragile Middle East ceasefire, and a Federal Reserve leadership transition were the significant events. All major indices ended higher, driven by resilient economic growth and strong corporate earnings. April marked a recovery from March lows, with the S&P 500 achieving record highs by early June, largely due to robust corporate earnings linked to AI capital spendi", "date_published": "2026-08-13T13:14:53+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "BSX"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "BSX", "name": "Boston Scientific Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/e71a4929-5366-46c6-b81d-15099a7fb8e0/"}]}}, {"id": "source:6bebd5c6d2f8662a74ba8d37058c7efaf4228f2893397c2e5001d65410bc2a61", "url": "https://finance.yahoo.com/markets/stocks/articles/edwards-climbs-14-3-months-125100456.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/edwards-climbs-14-3-months-125100456.html", "title": "Edwards Climbs 14% in 3 Months as Growth Strength Tests Valuation", "content_text": "Edwards Lifesciences Corporation EW shares have gained 14% in the past three months as growth across its structural-heart franchises has strengthened the operating case. Second-quarter results showed double-digit expansion in transcatheter aortic valve replacement and faster growth in transcatheter mitral and tricuspid therapies. The rally leaves investors balancing broader growth and raised 2026 expectations against a valuation that already reflects meaningful execution. EW's 3-Month Gain Meets a Premium Valuation EW trades at 28.8X forward 12-month EPS, above 27.3X for the Zacks sub-industry", "date_published": "2026-08-13T12:51:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "EWL", "BSX"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "EWL", "name": "Edwards Lifesciences Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/d182ff67-5fcd-48c1-9450-8975babb5883/"}, {"symbol": "BSX", "name": "Boston Scientific Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/e71a4929-5366-46c6-b81d-15099a7fb8e0/"}]}}, {"id": "source:44eba28bf78d020546e41c688eb9802fde66248b39f513d8609af0d73f4e7a33", "url": "https://finance.yahoo.com/healthcare/articles/whats-backing-abbotts-established-pharmaceuticals-124900457.html", "external_url": "https://finance.yahoo.com/healthcare/articles/whats-backing-abbotts-established-pharmaceuticals-124900457.html", "title": "What's Backing Abbott's Established Pharmaceuticals Division Growth", "content_text": "Abbott Laboratories' ABT Established Pharmaceuticals Division (\"EPD\") continues to be a solid growth contributor, supported by its broad portfolio of branded generic medicines and strong commercial presence across emerging markets. In the second quarter of 2026, EPD sales increased 8.4% on a reported basis and 8.7% on a comparable basis. Key Emerging Markets delivered 10.7% comparable sales growth, driven by double-digit growth in several countries across Latin America and Asia Pacific. The strong performance highlights the benefits of EPD's diversified geographic footprint and its ability to ", "date_published": "2026-08-13T12:49:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "ABL", "BSX"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ABL", "name": "Abbott Laboratories", "sentiment_url": "https://sharemaestro.com/sentiment/5aee0440-2bab-4e30-b16e-000aa7acbda4/"}, {"symbol": "BSX", "name": "Boston Scientific Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/e71a4929-5366-46c6-b81d-15099a7fb8e0/"}]}}, {"id": "source:e62631285d7721245ec3e28a17d057d0d95d03a031f7951167d433420fe5c569", "url": "https://finance.yahoo.com/healthcare/articles/wolfe-research-downgrades-stryker-upgrades-123705436.html", "external_url": "https://finance.yahoo.com/healthcare/articles/wolfe-research-downgrades-stryker-upgrades-123705436.html", "title": "Wolfe Research downgrades Stryker, upgrades Abbott in med-tech shuffle", "content_text": "Investing.com -- Wolfe Research made two rating changes across large-cap medical devices, downgrading Stryker while upgrading Abbott Laboratories on Thursday. Analyst Mike Polark cut Stryker to Peer Perform, citing a demanding second-half setup following the company's March cyber disruption. He said the June quarter \"wasn't a huge catch up thus year not yet de-risked,\" leaving \"a higher-than-normal burden on 2H to deliver.\" As a result, Wolfe sees the near-term skew to estimates \"leans negative,\" with growth \"more likely to slow to 8% vs speed up to 10% in 2027.\" The firm flagged that Stryker'", "date_published": "2026-08-13T12:37:05+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Analyst action", "ABL"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ABL", "name": "Abbott Laboratories", "sentiment_url": "https://sharemaestro.com/sentiment/5aee0440-2bab-4e30-b16e-000aa7acbda4/"}]}}, {"id": "source:818098fc4a692a35ff61040a99130017fbfd277122b5d292fc6289de826c88f3", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxNTkFUMDlFS1VPcEhES1d1V1RVd1ZjS2tuNHB0RXNZUjh6SlhrV1Y4NGVCMmdoc1JQbjk0RHdRc0dOZU40Zi0yOW45UlhCOFd4bnVUMlBTU0ZpdlFVaWZfbC1kV1NYclJQSDB0MGdLZTd2RlR3MWhsQWhQOUV5bjVmQ3kzMDRxZVE4RWliNndfVTBnd1JMZnhiWnBKMFJPdDNLRjFGVDhWMXdsWEs2Y3V1OVBEQzZNaVVncE5r?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxNTkFUMDlFS1VPcEhES1d1V1RVd1ZjS2tuNHB0RXNZUjh6SlhrV1Y4NGVCMmdoc1JQbjk0RHdRc0dOZU40Zi0yOW45UlhCOFd4bnVUMlBTU0ZpdlFVaWZfbC1kV1NYclJQSDB0MGdLZTd2RlR3MWhsQWhQOUV5bjVmQ3kzMDRxZVE4RWliNndfVTBnd1JMZnhiWnBKMFJPdDNLRjFGVDhWMXdsWEs2Y3V1OVBEQzZNaVVncE5r?oc=5", "title": "Siemens Healthineers Aktie: Gewinnprognose auf 2,35\u20132,45 Euro angehoben", "content_text": "Siemens Healthineers Aktie: Gewinnprognose auf 2,35\u20132,45 Euro angehoben", "date_published": "2026-08-13T12:04:09+00:00", "authors": [{"name": "B\u00f6rse Express"}], "tags": ["Market update", "SHL"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "SHL", "name": "Siemens Healthineers AG", "sentiment_url": "https://sharemaestro.com/sentiment/f59fc76d-202e-48de-ad9c-adf0d2b1a07d/"}]}}, {"id": "source:8e5c108a20b4f63962387c154682ee94c7236d3afba767978251b3a75ee704d5", "url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxNaDVzS0psUGdKamZBYzNRVWIyUDZvM1RrTi1TZkQyTG1MRXRxMl9Bc1NBSDVHRXowaFFCT0JwNFUxci1jcTdfMVZxdmItRjBRZGlJaHNpUS1xNjBjTV9SNHlNTThHTHhuVWswS2E0WUZUNjlMY0pET1hoZmxsQkZJYmw2d01uR2VhcXFzcUl2T1FfeUNLV0xWbm1uaXNka3pUYzl2cEJmRHFsbDVfbS1naHExMmlxVV9iR3h0bmJ5OGg2eVVrakRUV3gydTNxY3dNalg4?oc=5", "external_url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxNaDVzS0psUGdKamZBYzNRVWIyUDZvM1RrTi1TZkQyTG1MRXRxMl9Bc1NBSDVHRXowaFFCT0JwNFUxci1jcTdfMVZxdmItRjBRZGlJaHNpUS1xNjBjTV9SNHlNTThHTHhuVWswS2E0WUZUNjlMY0pET1hoZmxsQkZJYmw2d01uR2VhcXFzcUl2T1FfeUNLV0xWbm1uaXNka3pUYzl2cEJmRHFsbDVfbS1naHExMmlxVV9iR3h0bmJ5OGg2eVVrakRUV3gydTNxY3dNalg4?oc=5", "title": "Die Abbott-Laboratories-Aktie legt nach starken Quartalszahlen und solider Guidance zu", "content_text": "Die Abbott-Laboratories-Aktie legt nach starken Quartalszahlen und solider Guidance zu", "date_published": "2026-08-13T11:48:03+00:00", "authors": [{"name": "AD HOC NEWS"}], "tags": ["Guidance", "ABL"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ABL", "name": "Abbott Laboratories", "sentiment_url": "https://sharemaestro.com/sentiment/5aee0440-2bab-4e30-b16e-000aa7acbda4/"}]}}, {"id": "source:a2632d9d688886c44c97313164441d185eb5f3f8ef4797b8144ecc361a82a680", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxNcTJyTkljMFU0QjdXV3VVSEw0RHhNWUR0dEx5Z1JtYzlpUlFsQ1NkS25vamJ4elpQM2ZndEpEVFY3eHEwSlJac3Jtc1VwUmh0OGxrbE5sM09XQmx3VTd0RDd3QkRydDlNdUp2UnpTbWl1S3ZSd05uYUowNC1WS3pYTFJTTmFpWXVWOThBcA?oc=5", "external_url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxNcTJyTkljMFU0QjdXV3VVSEw0RHhNWUR0dEx5Z1JtYzlpUlFsQ1NkS25vamJ4elpQM2ZndEpEVFY3eHEwSlJac3Jtc1VwUmh0OGxrbE5sM09XQmx3VTd0RDd3QkRydDlNdUp2UnpTbWl1S3ZSd05uYUowNC1WS3pYTFJTTmFpWXVWOThBcA?oc=5", "title": "Eckert & Ziegler Aktie: Lizenzl\u00fccke dr\u00fcckt Ergebnis", "content_text": "Eckert & Ziegler Aktie: Lizenzl\u00fccke dr\u00fcckt Ergebnis", "date_published": "2026-08-13T09:57:06+00:00", "authors": [{"name": "Finanztrends"}], "tags": ["Market update", "EUZ"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "EUZ", "name": "Eckert & Ziegler SE", "sentiment_url": "https://sharemaestro.com/sentiment/451afbcd-39e0-41f6-816d-ddcebe221c0c/"}]}}, {"id": "source:c2cc5caff9329b2c44271043d2c6c60838bf70664d92bd5cbd1b632d92e05b7c", "url": "https://news.google.com/rss/articles/CBMifEFVX3lxTE1yM3Bva1ZpQWJzTzRnbEtzRDFtMWw4aWFrNGNGcFprS1NRNElFMHVrOW95MVFJUlIwdlFpNk5aY0ZHbW1mdWk1eHJYVGpSZnBUcm01R05xT0hwUlc0dHVaMFgzZzA1c1B0ZHJ1NXNRdEtJX09Sd1NQMHp2dmHSAYIBQVVfeXFMTkJ1RXVmTEctWnVnWlJxM0JVV0I4ODM4ZnNfYzZEbGJIcnlYQlE2cGROQ2NacWJUOUFTQmt0eFBjTE54bmpnUmhGM2pwM1FrR1Y1Zmx6UjdyTHRGTUNBSjNfRHdKTmJobF94UDFRM1dLR2tJT0gzQl8ybXdqSzNELUNvQQ?oc=5", "external_url": "https://news.google.com/rss/articles/CBMifEFVX3lxTE1yM3Bva1ZpQWJzTzRnbEtzRDFtMWw4aWFrNGNGcFprS1NRNElFMHVrOW95MVFJUlIwdlFpNk5aY0ZHbW1mdWk1eHJYVGpSZnBUcm01R05xT0hwUlc0dHVaMFgzZzA1c1B0ZHJ1NXNRdEtJX09Sd1NQMHp2dmHSAYIBQVVfeXFMTkJ1RXVmTEctWnVnWlJxM0JVV0I4ODM4ZnNfYzZEbGJIcnlYQlE2cGROQ2NacWJUOUFTQmt0eFBjTE54bmpnUmhGM2pwM1FrR1Y1Zmx6UjdyTHRGTUNBSjNfRHdKTmJobF94UDFRM1dLR2tJT0gzQl8ybXdqSzNELUNvQQ?oc=5", "title": "Eckert & Ziegler: Mehr Gewinn und Prognose best\u00e4tigt", "content_text": "Eckert & Ziegler: Mehr Gewinn und Prognose best\u00e4tigt", "date_published": "2026-08-13T08:17:09+00:00", "authors": [{"name": "4investors.de"}], "tags": ["Market update", "EUZ"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "EUZ", "name": "Eckert & Ziegler SE", "sentiment_url": "https://sharemaestro.com/sentiment/451afbcd-39e0-41f6-816d-ddcebe221c0c/"}]}}, {"id": "source:19c448bd17978ba69542b6669c5c4089a3b8247df77ddaecd09b8b118d2b7c96", "url": "https://finance.yahoo.com/healthcare/articles/abbott-laboratories-abt-ties-lingo-211304863.html", "external_url": "https://finance.yahoo.com/healthcare/articles/abbott-laboratories-abt-ties-lingo-211304863.html", "title": "Abbott Laboratories (ABT) Ties Lingo Glucose Data To AI Health Tools", "content_text": "Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Abbott Laboratories (NYSE:ABT) and Google Health announced a multi year partnership to integrate Abbott's Lingo biowearable glucose data with Google's AI driven consumer health tools. The collaboration aims to feed continuous glucose monitoring insights into the Google Health app to support personalized metabolic health tracking and coaching. The companies plan to run one of the largest real world metabolic health studies using anonymized Lingo data combined with Google's AI ", "date_published": "2026-08-12T21:13:04+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Deals and strategy", "ABL"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ABL", "name": "Abbott Laboratories", "sentiment_url": "https://sharemaestro.com/sentiment/5aee0440-2bab-4e30-b16e-000aa7acbda4/"}]}}, {"id": "source:478d8bb2a6d5519be03a4d870b9cf9d1e0273bb941092e8b7e6dd574e50a5403", "url": "https://news.google.com/rss/articles/CBMiZ0FVX3lxTE1NbE4yeVFNZ0E5OEx6cmFLR3FEOWd4Ql91bUlsaVNGNTdNRlFrR2c0WGtVNDBXaVktakIxSy12OGxKUkkyUUVPUkFURWFjYjhKRkVhT29DZFlYM1k0SzhPTnhRZElBZjA?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiZ0FVX3lxTE1NbE4yeVFNZ0E5OEx6cmFLR3FEOWd4Ql91bUlsaVNGNTdNRlFrR2c0WGtVNDBXaVktakIxSy12OGxKUkkyUUVPUkFURWFjYjhKRkVhT29DZFlYM1k0SzhPTnhRZElBZjA?oc=5", "title": "ABBOTT LABORATORIES AKTIE: AI-Analysen, Prognose & Kursziel", "content_text": "ABBOTT LABORATORIES AKTIE: AI-Analysen, Prognose & Kursziel", "date_published": "2026-08-12T20:22:19+00:00", "authors": [{"name": "finanzen.net"}], "tags": ["Market update", "ABL"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ABL", "name": "Abbott Laboratories", "sentiment_url": "https://sharemaestro.com/sentiment/5aee0440-2bab-4e30-b16e-000aa7acbda4/"}]}}, {"id": "source:7835a6b4b376fa6f740670085bc029bc18c05ead14857e55d06d331eda00396f", "url": "https://finance.yahoo.com/markets/stocks/articles/dxcm-stock-worth-buying-growth-183600592.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/dxcm-stock-worth-buying-growth-183600592.html", "title": "Is DXCM Stock Worth Buying as Growth Improves but Valuation Stretches?", "content_text": "DexCom, Inc. DXCM is entering the second half of 2026 with healthier margins, broader reimbursement and a larger continuous glucose monitoring opportunity. The investment question is whether that improving setup is enough to justify a premium valuation. Growth catalysts remain visible across U.S. coverage, product upgrades and international expansion. Yet competition, litigation and a forward earnings multiple above key benchmarks leave less room for execution misses. DXCM's Growth Case Is Still Broadening DexCom's addressable market is widening beyond intensive insulin users. All four of the ", "date_published": "2026-08-12T18:36:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "ABL"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "ABL", "name": "Abbott Laboratories", "sentiment_url": "https://sharemaestro.com/sentiment/5aee0440-2bab-4e30-b16e-000aa7acbda4/"}]}}, {"id": "source:cb1fb61e2d7b4c9de7e8f3ba544e3579767d3406ea22a6d11486614a7eb1e9aa", "url": "https://finance.yahoo.com/healthcare/articles/dxcm-stock-nearly-35-ytd-183400790.html", "external_url": "https://finance.yahoo.com/healthcare/articles/dxcm-stock-nearly-35-ytd-183400790.html", "title": "DXCM Stock Up Nearly 35% YTD: Will the Uptrend Continue in the Rest of 2026?", "content_text": "DexCom DXCM stock has rebounded sharply in 2026, gaining 34.8% after falling 14.7% in 2025, as investors increasingly recognize the company's improving growth profile and expanding continuous glucose monitoring (CGM) opportunity. The company's share price performance so far this year has outperformed the industry's 6.9% decline and S&P 500 Index's 13.1% gain. The second-quarter performance reflected recovery, with revenues rising 13% year over year and organic growth reaching 12%. U.S. revenues increased 11%, while international revenues jumped 19%, reflecting broader reimbursement, market-sha", "date_published": "2026-08-12T18:34:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "ABL"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "ABL", "name": "Abbott Laboratories", "sentiment_url": "https://sharemaestro.com/sentiment/5aee0440-2bab-4e30-b16e-000aa7acbda4/"}]}}, {"id": "source:0f3f921f4e754d1dc87f0170b5d5e6487b23b1075953275044ad300b7bd58823", "url": "https://finance.yahoo.com/healthcare/articles/dexcoms-raised-2026-outlook-sustain-183300821.html", "external_url": "https://finance.yahoo.com/healthcare/articles/dexcoms-raised-2026-outlook-sustain-183300821.html", "title": "Can DexCom's Raised 2026 Outlook Sustain Stronger Margin Momentum?", "content_text": "DexCom, Inc. DXCM raised its 2026 revenue and margin outlook after a stronger second quarter, shifting more attention toward profitability. The question is whether better gross margin and operating leverage can persist as organic growth improves. The guidance increase is encouraging, but foreign exchange, manufacturing investment and product-transition costs still matter. Sustaining the margin step-up will require continued execution across products, geographies and channels. DexCom's Q2 Results Reset the 2026 Baseline DexCom reported second-quarter 2026 revenues of $1.31 billion, up 13.1% yea", "date_published": "2026-08-12T18:33:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "ABL"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "ABL", "name": "Abbott Laboratories", "sentiment_url": "https://sharemaestro.com/sentiment/5aee0440-2bab-4e30-b16e-000aa7acbda4/"}]}}, {"id": "source:e2e53014098505128ba9b042fa06f1f76e2cbe50dbb782d539fd1cf552748935", "url": "https://finance.yahoo.com/markets/stocks/articles/dxcm-rallies-52-5-3-183300640.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/dxcm-rallies-52-5-3-183300640.html", "title": "DXCM Rallies 52.5% in 3 Months. Can the Stock Keep Climbing From Here?", "content_text": "DexCom, Inc. DXCM shares have climbed 52.5% in the past three months, a sharp re-rating that raises the standard for further gains. The next leg depends less on momentum alone and more on whether earnings growth, margin expansion and new-market access can keep pace with higher expectations. Recent results support the fundamental case, but the stock's premium valuation leaves less room for disappointment. Investors now have to weigh improving execution against competition and litigation risk. DXCM's 52.5% Rally Outpaces Key Benchmarks DXCM's three-month gain easily exceeds the 18.3% rise for th", "date_published": "2026-08-12T18:33:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "ABL"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "ABL", "name": "Abbott Laboratories", "sentiment_url": "https://sharemaestro.com/sentiment/5aee0440-2bab-4e30-b16e-000aa7acbda4/"}]}}, {"id": "source:3ea6e701ff7683fcac8c3f9bcb8cf44f16546528c61754b8293901a2b441debc", "url": "https://finance.yahoo.com/markets/commodities/articles/latest-global-whey-protein-market-173000212.html", "external_url": "https://finance.yahoo.com/markets/commodities/articles/latest-global-whey-protein-market-173000212.html", "title": "[Latest] Global Whey Protein Market Size/Share Worth USD 26.04 Billion by 2034 at a 7.56% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)", "content_text": "Custom Market Insights [220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Whey Protein Market size & share revenue was valued at approximately USD 12.58 Billion in 2024 and is expected to reach USD 13.52 Billion in 2025 and is expected to reach around USD 26.04 Billion by 2034, at a CAGR of 7.56% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Abbott, Alpavit, Arla Foods, Carbery Group, Davisco Foods International, Inc., Fonterra Co-operative Group Lt", "date_published": "2026-08-12T17:30:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Guidance", "ABL"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "ABL", "name": "Abbott Laboratories", "sentiment_url": "https://sharemaestro.com/sentiment/5aee0440-2bab-4e30-b16e-000aa7acbda4/"}]}}, {"id": "source:236f34736a111bb242258345d7e1c88edda917f48b269c364f2bb5538f36f2f3", "url": "https://finance.yahoo.com/healthcare/articles/abbott-big-ten-bring-back-131400198.html", "external_url": "https://finance.yahoo.com/healthcare/articles/abbott-big-ten-bring-back-131400198.html", "title": "Abbott and Big Ten bring back 'We Give Blood' as U.S. faces blood supply crisis", "content_text": "\"We Give Blood\" brings together all 18 Big Ten\u00ae schools in a competition to drive the most blood donations and win $1 million from global healthcare company Abbott For only the second time in its history, the American Red Cross has declared a national blood crisis after donations dropped to a four-year summer low, threatening the availability of lifesaving blood for patients across the country Abbott and the Big Ten urge people to donate blood now and will count those early donations toward the competition, which officially kicks off Aug. 26 Anyone can donate blood anywhere in the U.S. between", "date_published": "2026-08-12T13:14:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "ABL"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ABL", "name": "Abbott Laboratories", "sentiment_url": "https://sharemaestro.com/sentiment/5aee0440-2bab-4e30-b16e-000aa7acbda4/"}]}}, {"id": "source:80a3b3777dc5d07225ba54fc3f7383d138d1d08013792e57a78293fc81738015", "url": "https://finance.yahoo.com/healthcare/articles/ai-enabled-imaging-modalities-market-112700624.html", "external_url": "https://finance.yahoo.com/healthcare/articles/ai-enabled-imaging-modalities-market-112700624.html", "title": "AI-Enabled Imaging Modalities Market Report: Evaluating AI Software Integration, FDA Approvals, and Competitive Strategies of GE HealthCare, Canon, Siemens, and Philips", "content_text": "Company Logo Accelerating clinical adoption highlighted by GE HealthCare's latest FDA clearance for AI-guided radiation planning, Canon Medical's AI deep-learning CT launch, and strong 2026 order books across Siemens Healthineers and Philips is transforming diagnostic workflows globally. This study delivers an in-depth competitive analysis, technology roadmap, and regional forecasts across MRI, CT, X-ray, Ultrasound, and PET modalities. AI-Enabled Imaging Modalities MarketAI-Enabled Imaging Modalities Market Dublin, Aug. 12, 2026 (GLOBE NEWSWIRE) -- The \"AI-Enabled Imaging Modalities Market - A Global and Regional Analysis: Focus on Modality, Application, 2026-2036\" has been added to ResearchAndMarkets.com's offering. The global AI-enabled imaging modalities market, initially valued at $3.41 billion in 2025, is projected to grow substantially, reaching $17.84 billion by 2036, with a remarkable compound annual growth rate (CAGR) of 16.24% from 2026 to 2036. The global AI-enabled imaging modalities market has been experiencing significant growth, driven by the increasing demand for accurate, faster, and workflow-efficient diagnostic imaging across healthcare systems. The rising volume of imaging procedures is creating strong demand for advanced imaging modalities that can improve diagnostic confidence, reduce turnaround times, and support higher patient throughput. AI-enabled imaging modalities, including X-ray, Magnetic Resonance Imaging (MRI) Systems, Computed Tomography, ultrasound, and other imaging modalities, are being increasingly used to support image acquisition, reconstruction, enhancement, detection, quantification, triage, reporting, and clinical decision-making. These systems help radiologists and clinicians manage growing diagnostic workloads by improving image quality, automating repetitive workflow steps, and enabling more consistent interpretation across clinical applications. Key innovations in AI-enabled reconstruction, image enhancement, automated detection, and workflow-integrated imaging platforms are accelerating the development of more efficient and scalable diagnostic imaging solutions. Technological advancements are reshaping the AI-enabled imaging modalities landscape, with innovations such as deep learning-based reconstruction, AI-assisted image analysis, automated segmentation, and integrated workflow intelligence playing a pivotal role in improving the accuracy and efficiency of imaging procedures. Despite the market's growth prospects, challenges such as high implementation costs, integration complexity, regulatory requirements, and concerns around clinical validation and reliability remain significant. However, ongoing investments in AI-ready imaging infrastructure, along with increasing collaborations between imaging original equipment manufacturers, healthcare providers, technology companies, and research institutions, are expected to drive further progress in the market. Market Introduction The global AI-enabled imaging modalities market has transformed, spurred by the convergence of imaging hardware, artificial intelligence, and connected healthcare IT infrastructure. Companies are increasingly integrating AI capabilities directly into imaging systems and enterprise platforms to enhance scanner performance, support clinical workflow intelligence, and enable more standardized diagnostic processes. Noteworthy advancements, such as embedded AI algorithms, automated protocol selection, intelligent image optimization, and interoperability with PACS, RIS, and EMR environments, underscore the industry's focus on moving beyond standalone software tools toward integrated imaging ecosystems. As healthcare providers prioritize productivity, scalability, and consistency in diagnostic services, innovations in AI-enabled imaging modalities are expected to shape the market's trajectory, positioning these technologies as central to next-generation imaging infrastructure and data-driven radiology operations. I", "date_published": "2026-08-12T11:27:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "SHL", "PHI1"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "SHL", "name": "Siemens Healthineers AG", "sentiment_url": "https://sharemaestro.com/sentiment/f59fc76d-202e-48de-ad9c-adf0d2b1a07d/"}, {"symbol": "PHI1", "name": "Koninklijke Philips N.V.", "sentiment_url": "https://sharemaestro.com/sentiment/1cc4de78-0344-4bf2-8f9e-a385142353b4/"}]}}, {"id": "source:4d2e178044b7f8ce040de8c6656f07deff97997333471c1d03a1caa5b7cad06f", "url": "https://finance.yahoo.com/markets/stocks/articles/1-semiconductor-stock-long-term-060522696.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/1-semiconductor-stock-long-term-060522696.html", "title": "1 Semiconductor Stock for Long-Term Investors and 2 Facing Challenges", "content_text": "1 Semiconductor Stock for Long-Term Investors and 2 Facing Challenges Semiconductors are the silicon backbone of the digital revolution. The amount of data we ingest is also increasing exponentially, leading to elevated demand for chips with more processing power. This secular trend bodes well for the industry, which has posted a six-month gain of 50.2% and beaten the S&P 500 by 39.1 percentage points. Although these businesses have produced results lately, investors should tread carefully as not all companies are equipped for the next technological innovation. On that note, here is one semiconductor stock boasting a durable advantage and two we're passing on. Two Semiconductor Stocks to Sell: NXP Semiconductors (NXPI) Market Cap: $60.45 billion Spun off from Dutch electronics giant Philips in 2006, NXP Semiconductors (NASDAQ: NXPI) is a designer and manufacturer of chips used in autos, industrial manufacturing, mobile devices, and communications infrastructure. Why Does NXPI Give Us Pause? Products and services are facing end-market challenges during this cycle, as seen in its flat sales over the last two years Estimated sales growth of 15.4% for the next 12 months is soft and implies weaker demand NXP Semiconductors's stock price of $240.50 implies a valuation ratio of 13.9x forward P/E. Check out our free in-depth research report to learn more about why NXPI doesn't pass our bar. Universal Display (OLED) Market Cap: $4.19 billion Serving major consumer electronics manufacturers, Universal Display (NASDAQ:OLED) is a provider of organic light emitting diode (OLED) technologies used in display and lighting applications. Why Does OLED Fall Short? Sales tumbled by 1.3% annually over the last two years, showing market trends are working against it during this cycle Demand will likely be soft over the next 12 months as Wall Street's estimates imply tepid growth of 8.2% Earnings per share lagged its peers over the last five years as they only grew by 1.1% annually At $91.10 per share, Universal Display trades at 19.3x forward P/E. If you're considering OLED for your portfolio, see our FREE research report to learn more. One Semiconductor Stock to Watch: Applied Materials (AMAT) Market Cap: $428.1 billion Founded in 1967 as the first company to develop tools for other businesses in the semiconductor industry, Applied Materials (NASDAQ:AMAT) is the largest provider of semiconductor wafer fabrication equipment. Why Are We Fans of AMAT? Highly efficient business model is illustrated by its impressive 29.1% operating margin Share repurchases have increased shareholder returns as its annual earnings per share growth of 13.2% exceeded its revenue gains over the last five years ROIC punches in at 46.2%, illustrating management's expertise in identifying profitable investments Story Continues Applied Materials is trading at $542.22 per share, or 34.9x forward P/E. Is now the time to initiate a position? See for yourself in our comprehensive research report, it's free. Stocks We Like Even More ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren't just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum \u2014 both boxes checked at the same time. Find out which stocks our AI platform is flagging this week. See this week's Strong Momentum stocks \u2014 FREE. Get Our Strong Momentum Stocks for Free HERE. Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+214% between June 2020 and June 2025). Find your next big winner with StockStory today. View Comments", "date_published": "2026-08-12T06:05:22+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "PHI1"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "PHI1", "name": "Koninklijke Philips N.V.", "sentiment_url": "https://sharemaestro.com/sentiment/1cc4de78-0344-4bf2-8f9e-a385142353b4/"}]}}, {"id": "source:7c9f436edfd2f1a83ac69b53be1de901395c293665ab59dc4c3293a88af7de05", "url": "https://news.google.com/rss/articles/CBMiZEFVX3lxTE0xSlVIOHZXeWQxREFHa3duSlZCMW1Tb1RCYkNLUU9KRXlqV2U1Ym05SFBneHdGSGk4TmRuakk1YnJqeFlNNDNnZnRjcU44NXdOeEZiQk9ERVpLYnhPUkV3dlRQeEI?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiZEFVX3lxTE0xSlVIOHZXeWQxREFHa3duSlZCMW1Tb1RCYkNLUU9KRXlqV2U1Ym05SFBneHdGSGk4TmRuakk1YnJqeFlNNDNnZnRjcU44NXdOeEZiQk9ERVpLYnhPUkV3dlRQeEI?oc=5", "title": "BOSTON SCIENTIFIC AKTIE: AI-Analysen, Prognose & Kursziel", "content_text": "BOSTON SCIENTIFIC AKTIE: AI-Analysen, Prognose & Kursziel", "date_published": "2026-08-12T05:05:07+00:00", "authors": [{"name": "finanzen.net"}], "tags": ["Market update", "BSX"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "BSX", "name": "Boston Scientific Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/e71a4929-5366-46c6-b81d-15099a7fb8e0/"}]}}, {"id": "source:a93731d0c9c40eb23dcb21e7d72b4b1b03117182e350815ead3bff07ebac932a", "url": "https://finance.yahoo.com/video/arrow-exploration-confirms-four-zones-174110053.html", "external_url": "https://finance.yahoo.com/video/arrow-exploration-confirms-four-zones-174110053.html", "title": "Arrow Exploration confirms four zones at Icaco 3, opens up ~10 new drilling locations", "content_text": "Arrow Exploration Corp (TSX-V:AXL, AIM:AXL, OTC:CSTPF) CEO Marshall Abbott tells Proactive's Stephen Gunnion that the Icaco 3 well has confirmed up to four hydrocarbon-bearing zones in the Icaco extension of the Tapir Block in Colombia, opening almost 10 additional development locations across the Ubaque, Guadalupe and Carbonera C7 intervals. The IC-HZ4 and IC-HZ5 horizontal wells encountered a record Ubaque thickness of over 100 feet, containing 13.7 API crude, with Abbott saying the Ubaque trend extends across the northern part of the Tapir Block, supporting further development drilling. Wit", "date_published": "2026-08-11T17:41:10+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "ABL"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "ABL", "name": "Abbott Laboratories", "sentiment_url": "https://sharemaestro.com/sentiment/5aee0440-2bab-4e30-b16e-000aa7acbda4/"}]}}, {"id": "source:931caa2ad66799ec95a108f37ebe2326c7f2d5b8f3a0f784ace0a25ae4da0353", "url": "https://finance.yahoo.com/markets/stocks/articles/investors-buy-inogen-low-valuation-162200792.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/investors-buy-inogen-low-valuation-162200792.html", "title": "Should Investors Buy Inogen as Low Valuation Meets Execution Risk?", "content_text": "Inogen, Inc. INGN trades at a steep sales-multiple discount even as second-quarter 2026 margins improved and international demand remained firm. The disconnect creates an interesting setup, but the operating recovery is not yet broad-based. Investors must weigh better cost control, expanding respiratory offerings and a debt-free balance sheet against persistent pressure in U.S. direct sales and rentals. That mix supports patience rather than a simple value-driven call. Inogen, Inc Price and ConsensusInogen, Inc Price and Consensus Inogen, Inc price-consensus-chart | Inogen, Inc Quote Inogen's Valuation Offers a Wide Discount INGN trades at 0.4X forward 12-month sales, far below 4.2X for its Zacks sub-industry and 2.2X for the broader Zacks sector. The gap shows how little investors are currently paying for each dollar of expected sales. The stock also sits below its five-year median multiple of 0.6X, after ranging from 0.3X to 3.8X over that span. The discount can provide rerating potential, but it also reflects skepticism about the durability of Inogen's turnaround. INGN's Margin Progress Strengthens the Case Second-quarter adjusted gross margin improved 65 basis points year over year to 45.6%, helped by cost improvements and lower warranty expenses. Adjusted operating loss narrowed to $1.3 million from $2.6 million, showing better expense discipline.Zacks Investment Research Image Source: Zacks Investment Research Research and development spending still rose as Inogen funded clinical evidence generation and new-product development. That balance matters because the company needs operating leverage without starving the respiratory portfolio initiatives intended to support future growth. Inogen's Growth Mix Is Shifting International sales increased 14.8% to $41.3 million in the second quarter, marking a 10th consecutive quarter of double-digit international growth. Inogen is expanding U.S. business-to-business relationships as home medical equipment providers increasingly start oxygen patients on portable concentrators. The broader respiratory market includes ResMed Inc. RMD, whose Sleep and Breathing Health business sells CPAP systems, masks and related solutions. Koninklijke Philips N.V. PHG also operates a Sleep & Respiratory Care business, underscoring the established competition around adjacent respiratory categories.Zacks Investment Research Image Source: Zacks Investment Research INGN Still Faces Material Execution Risks U.S. sales fell 2.3% to $42.3 million, while U.S. rental revenues declined 11.8% to $11.6 million. The faster shift toward first-start portable oxygen concentrators at home medical equipment providers is narrowing Inogen's traditional direct-to-consumer and rental funnel. Story Continues Reimbursement dependence, distributor inventory timing, foreign exchange exposure, supply-chain uncertainty and pricing competition add further risk. Inogen must prove that gains in business-to-business sales, international markets and new products can offset structural weakness in its legacy channels. Inogen's Balance Sheet Preserves Flexibility Inogen ended the second quarter with $87.3 million in cash and cash equivalents and no outstanding debt. That financial position gives the company flexibility to support commercial expansion, product development and clinical programs while it works through the U.S. channel transition. The company generated $2.9 million of operating cash flow in the quarter. Still, liquidity alone does not resolve execution risk, making disciplined capital allocation important as Inogen funds multiple growth initiatives while pursuing profitability. INGN's Signals Support a Patient Stance The low valuation, better margins and international momentum keep the investment case alive, but the U.S. channel reset remains the central test. Investors may want clearer evidence that business-to-business growth and newer respiratory products can produce steadier companywide growth. INGN currently carries a Z", "date_published": "2026-08-11T16:22:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "PHI1"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "PHI1", "name": "Koninklijke Philips N.V.", "sentiment_url": "https://sharemaestro.com/sentiment/1cc4de78-0344-4bf2-8f9e-a385142353b4/"}]}}, {"id": "source:9b0747406a31f261a432fba0c0e5eb1aba2c71244b46ea5c19d6bb0ddefce0e0", "url": "https://finance.yahoo.com/healthcare/articles/abbott-google-launch-first-kind-130000853.html", "external_url": "https://finance.yahoo.com/healthcare/articles/abbott-google-launch-first-kind-130000853.html", "title": "Abbott and Google launch first-of-its-kind partnership to transform everyday health through glucose insights and AI", "content_text": "Multi-year collaboration combines ongoing glucose insights from Abbott's Lingo biowearable with Google Health's technology to create a more comprehensive view of personal health Partnership includes a large-scale research study to better inform artificial intelligence (AI) coaching available in the Google Health app and future Lingo product features Lingo, Abbott's over-the-counter continuous glucose monitor (CGM), helps people understand the impact of nutrition, activity, sleep and stress on their glucose so they can make meaningful lifestyle changes ABBOTT PARK, Ill., Aug. 11, 2026 /PRNewswi", "date_published": "2026-08-11T13:00:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Deals and strategy", "ABL"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ABL", "name": "Abbott Laboratories", "sentiment_url": "https://sharemaestro.com/sentiment/5aee0440-2bab-4e30-b16e-000aa7acbda4/"}]}}, {"id": "source:8e160b0a5f60e252ab93dfa8f9231797d251b8f53394b88e95bd7f3fe4407139", "url": "https://finance.yahoo.com/healthcare/articles/abbvie-piles-8-billion-debt-110500324.html", "external_url": "https://finance.yahoo.com/healthcare/articles/abbvie-piles-8-billion-debt-110500324.html", "title": "AbbVie Piles on $8 Billion in Debt for Its Apogee Deal -- Should Dividend Investors Worry?", "content_text": "AbbVie (NYSE: ABBV) is aiming high with its $10.6 billion planned purchase of Apogee Therapeutics (NASDAQ: APGE). The deal, pending regulatory approvals, is expected to close in the third quarter. The move is designed to supplement the pharmaceutical giant's already strong immunology portfolio. However, to fund the acquisition of the biotech company, AbbVie is taking on significant debt, which concerns some analysts. The payoff, AbbVie says, likely won't come for six years, with the deal not expected to boost adjusted earnings per share (EPS) until 2032. Missed Nvidia in 2009? This Rare Signal", "date_published": "2026-08-11T11:05:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Deals and strategy", "ABL"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "ABL", "name": "Abbott Laboratories", "sentiment_url": "https://sharemaestro.com/sentiment/5aee0440-2bab-4e30-b16e-000aa7acbda4/"}]}}, {"id": "source:1e0e00363db074638cbc860140fc49273515a220d295b2895102a2c88136eada", "url": "https://finance.yahoo.com/healthcare/articles/pulsed-field-ablation-global-market-090500258.html", "external_url": "https://finance.yahoo.com/healthcare/articles/pulsed-field-ablation-global-market-090500258.html", "title": "Pulsed Field Ablation Global Market Report 2026 Now Available - Profiles Boston Scientific, Medtronic, Biosense Webster, and 15 Other Players", "content_text": "Company Logo Pulsed Field Ablation MarketPulsed Field Ablation Market Dublin, Aug. 11, 2026 (GLOBE NEWSWIRE) -- The \"Pulsed Field Ablation Market by Therapeutic Area, Product Components, Application Area, Source of Ablation, Key Geographical Regions, and Sales Forecast of Leading Players - Trends and Forecast till 2035\" has been added to ResearchAndMarkets.com's offering. The global pulsed field ablation market is projected to expand from approximately USD 3.2 billion in 2026 to USD 14.6 billion by 2035, representing a compound annual growth rate of 18.4% during the forecast period. Rising atr", "date_published": "2026-08-11T09:05:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Guidance", "BSX"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "BSX", "name": "Boston Scientific Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/e71a4929-5366-46c6-b81d-15099a7fb8e0/"}]}}, {"id": "source:d56bac5c876b80aeeca49e31e5dfbdb723366f1c47826404898c7d2ffbcfb38b", "url": "https://www.nasdaq.com/articles/royal-philips-and-exor-update-long-term-relationship-agreement", "external_url": "https://www.nasdaq.com/articles/royal-philips-and-exor-update-long-term-relationship-agreement", "title": "Royal Philips And Exor Update Long-Term Relationship Agreement", "content_text": "(RTTNews) - Royal Philips (PHG), a health technology company, and Exor N.V., an investment company, announced that they have agreed to update their long-term relationship agreement. Royal Philips provides image-guided therapy, diagnostic imaging, ultrasound, monitoring, and enterprise informatics and made approximately 18 billion euros in sales in 2025. Exor is the largest shareholder in companies including Ferrari, Philips, CNH and Stellantis. In August 2023, Royal Philips and Exor entered into a relationship agreement, under which Exor bought a 15% shareholding in Royal Philips to provide co", "date_published": "2026-08-11T08:14:10+00:00", "authors": [{"name": "nasdaq.com"}], "tags": ["Market update", "PHI1"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "PHI1", "name": "Koninklijke Philips N.V.", "sentiment_url": "https://sharemaestro.com/sentiment/1cc4de78-0344-4bf2-8f9e-a385142353b4/"}]}}, {"id": "source:1c8e1137cbdd39b6aea8b289794d24a367c007eba5a577b44e7c22e467624381", "url": "https://finance.yahoo.com/healthcare/articles/abbott-vs-medtronic-consistent-growth-224625108.html", "external_url": "https://finance.yahoo.com/healthcare/articles/abbott-vs-medtronic-consistent-growth-224625108.html", "title": "Abbott vs. Medtronic: Is Consistent Growth Better Than a Turnaround Story?", "content_text": "Abbott Laboratories (NYSE:ABT) and Medtronic (NYSE:MDT) are both prominent names in the Medtech space. Abbott Laboratories (NYSE:ABT) delivered strong fiscal Q2 2026 results, beating quarterly estimates and raising its annual profit forecast as robust demand for its cancer diagnostics and medical devices businesses helped ease investor concerns surrounding procedure volumes. Medtronic (NYSE:MDT), meanwhile, continued to build on its turnaround, reporting its strongest annual revenue growth in a decade as several high-growth platforms gained momentum. So, which is the more compelling long-term ", "date_published": "2026-08-10T22:46:25+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "ABL"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ABL", "name": "Abbott Laboratories", "sentiment_url": "https://sharemaestro.com/sentiment/5aee0440-2bab-4e30-b16e-000aa7acbda4/"}]}}, {"id": "source:d3ab2b7502c0abaac5cde1db78f3d61c3eea5a4004021eb3d7b5a05c0c8bffc5", "url": "https://finance.yahoo.com/healthcare/articles/johnson-johnson-vs-abbott-laboratories-204959195.html", "external_url": "https://finance.yahoo.com/healthcare/articles/johnson-johnson-vs-abbott-laboratories-204959195.html", "title": "Johnson & Johnson vs Abbott Laboratories: Which Healthcare Giant Offers the More Compelling Growth Story After Earnings?", "content_text": "Johnson & Johnson (NYSE:JNJ) delivered strong fiscal Q2 2026 results, with sales for the quarter growing nearly 7% to $25.31 \u2060billion, above analysts' average estimate of about $25.05 billion. Adjusted earnings per share reached $2.90, surpassing the expectation of $2.85. The company also raised its guidance and stated that it is on track to meet its 2026 goal of over $100 billion in annual revenue for the first time in its 140-year history. Abbott Laboratories (NYSE:ABT) also beat its quarterly estimates in its fiscal Q2 2026 results while also raising its annual profit forecast, with strong ", "date_published": "2026-08-10T20:49:59+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "ABL"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "ABL", "name": "Abbott Laboratories", "sentiment_url": "https://sharemaestro.com/sentiment/5aee0440-2bab-4e30-b16e-000aa7acbda4/"}]}}, {"id": "source:7703f3386bdf9c30a1da14a667b6a0c799897c5eec25c59526fc361155dd0b1c", "url": "https://finance.yahoo.com/markets/stocks/articles/boston-scientific-ceo-mahoney-buys-174601248.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/boston-scientific-ceo-mahoney-buys-174601248.html", "title": "Boston Scientific CEO Mahoney Buys More Than 200k Shares for $10 Million. What Does This Mean for Investors in 2026?", "content_text": "Michael F. Mahoney, Chairman, President & CEO of Boston Scientific Corporation (NYSE:BSX), purchased 186,240 shares of common stock at $48.34 per share on August 3, 2026. SEC Form 4 filing. Transaction summary Metric Value Transaction value $10.1 million Shares purchased 208,359 Post-transaction shares (total) 1,612,143 Post-transaction shares (directly held) 1,590,024 Post-transaction shares (indirectly held) 22,119 Post-transaction value $78.08 million Transaction value based on SEC Form 4 weighted average purchase price ($48.34); post-transaction value based on August 03, 2026 market close ", "date_published": "2026-08-10T17:46:01+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "BSX"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "BSX", "name": "Boston Scientific Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/e71a4929-5366-46c6-b81d-15099a7fb8e0/"}]}}, {"id": "source:dea1ac67270a03f004103eea2178674dd0f38aca435a522598916a1c0305c97e", "url": "https://news.google.com/rss/articles/CBMiaEFVX3lxTE82TTktN3NwQ2wwcGo2RTVuNzRxS2NYTE1OYU1kSFlfcVJmRTNMM3NRY3hfUV90UGxqTFI4Ulp2VUxkaUNXV2E0YVU3d1lhRGVNLUk2ZG5JdlNUamgwNkM4aFdqX1RZUGxW?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiaEFVX3lxTE82TTktN3NwQ2wwcGo2RTVuNzRxS2NYTE1OYU1kSFlfcVJmRTNMM3NRY3hfUV90UGxqTFI4Ulp2VUxkaUNXV2E0YVU3d1lhRGVNLUk2ZG5JdlNUamgwNkM4aFdqX1RZUGxW?oc=5", "title": "EDWARDS LIFESCIENCES AKTIE: AI-Analysen, Prognose & Kursziel", "content_text": "EDWARDS LIFESCIENCES AKTIE: AI-Analysen, Prognose & Kursziel", "date_published": "2026-08-10T14:56:32+00:00", "authors": [{"name": "finanzen.net"}], "tags": ["Market update", "EWL"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "EWL", "name": "Edwards Lifesciences Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/d182ff67-5fcd-48c1-9450-8975babb5883/"}]}}, {"id": "source:390765aa7addb2236810f0ab23ac9e6d6081e06b54be92e59ed0289d5d56666d", "url": "https://finance.yahoo.com/markets/stocks/articles/buy-hold-sell-abt-stock-144300730.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/buy-hold-sell-abt-stock-144300730.html", "title": "Should You Buy, Hold or Sell ABT Stock Amid Medical Devices Boom?", "content_text": "Abbott Laboratories' ABT Medical Devices remains its largest segment and continues to benefit from a strong pipeline of new product launches and growing adoption across cardiovascular care and diabetes management. The segment is well positioned to capitalize on the expanding global medical devices market. According to Fortune Business Insights, the global medical devices market was valued at $572.31 billion in 2025 and is projected to increase from $604.99 billion in 2026 to $1.03 trillion by 2034, reflecting a CAGR of 6.9% over the forecasted period. Given this favorable industry backdrop, Ab", "date_published": "2026-08-10T14:43:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "ABL", "BSX"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "ABL", "name": "Abbott Laboratories", "sentiment_url": "https://sharemaestro.com/sentiment/5aee0440-2bab-4e30-b16e-000aa7acbda4/"}, {"symbol": "BSX", "name": "Boston Scientific Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/e71a4929-5366-46c6-b81d-15099a7fb8e0/"}]}}, {"id": "source:7ffc061d9b5a790ba2b6010f65d261b2fd6ad0434b0781cc9df671cd86e0db66", "url": "https://news.google.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?oc=5", "external_url": "https://news.google.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?oc=5", "title": "Boston Scientific (BSX) Nach R\u00fcckrufen Und Gek\u00fcrzter Prognose Noch G\u00fcnstig Oder Schon Eingepreist?", "content_text": "Boston Scientific (BSX) Nach R\u00fcckrufen Und Gek\u00fcrzter Prognose Noch G\u00fcnstig Oder Schon Eingepreist?", "date_published": "2026-08-09T22:34:38+00:00", "authors": [{"name": "simplywall.st"}], "tags": ["Market update", "BSX"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "BSX", "name": "Boston Scientific Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/e71a4929-5366-46c6-b81d-15099a7fb8e0/"}]}}, {"id": "source:82ab4d8e3d459602cfbcb4a78d96719417b000b598eeaae375fc6b467a40ec18", "url": "https://finance.yahoo.com/markets/crypto/articles/kraken-delisting-deadline-nears-holders-212908309.html", "external_url": "https://finance.yahoo.com/markets/crypto/articles/kraken-delisting-deadline-nears-holders-212908309.html", "title": "Kraken Delisting Deadline Nears: Holders of 21 Tokens Risk Near-Zero Payouts", "content_text": "kraken delisting. Photo by BeInCrypto Kraken is entering the final stage of its latest delisting cycle, giving holders of 21 tokens until August 27 at 14:00 UTC to withdraw their assets. Afterwards, the exchange begins automatically liquidating remaining balances into markets it warns may have limited or no liquidity. The scheduled delisting, first announced in May, affects assets that no longer meet Kraken's internal performance or compliance standards. Key Dates and Affected Tokens Kraken halted trading and deposits for the affected assets on May 29. The August 27 deadline marks the final op", "date_published": "2026-08-09T21:29:08+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Balance sheet", "BSX"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "BSX", "name": "Boston Scientific Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/e71a4929-5366-46c6-b81d-15099a7fb8e0/"}]}}, {"id": "source:ef424361523001fb111a4ab4bac4d5048b6f2b833bc552ac1cabc975024b6873", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxPcFFrTDJRSEZwV1dxNENabjNlNDM2Y3JKOU45cUNZTkRBOHhFXzI2ZC1DU0xoTEtvT2JQQl9KRVExZ3BMNjN1VXE4YjdvdEx0ODZnNlloN1JUVGczMC1sUEgzMU1uRVNBV05ISE5mR2J5Y0JsczFqeWpkZXdURm92VXQwV0ZwRzV6aC1mbWFoSTExbExEQjlGUXdkTEViYWQ2c3JlUVVZcG01dzVubHpTdHV0bFloMUpLOGFxYUNjeEgxN1JMSDBhbzU4Mmw?oc=5", "external_url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxPcFFrTDJRSEZwV1dxNENabjNlNDM2Y3JKOU45cUNZTkRBOHhFXzI2ZC1DU0xoTEtvT2JQQl9KRVExZ3BMNjN1VXE4YjdvdEx0ODZnNlloN1JUVGczMC1sUEgzMU1uRVNBV05ISE5mR2J5Y0JsczFqeWpkZXdURm92VXQwV0ZwRzV6aC1mbWFoSTExbExEQjlGUXdkTEViYWQ2c3JlUVVZcG01dzVubHpTdHV0bFloMUpLOGFxYUNjeEgxN1JMSDBhbzU4Mmw?oc=5", "title": "Abbott Laboratories Aktie: 410. Quartalsdividende am 17. August", "content_text": "Abbott Laboratories Aktie: 410. Quartalsdividende am 17. August", "date_published": "2026-08-09T01:34:00+00:00", "authors": [{"name": "AD HOC NEWS"}], "tags": ["Market update", "ABL"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ABL", "name": "Abbott Laboratories", "sentiment_url": "https://sharemaestro.com/sentiment/5aee0440-2bab-4e30-b16e-000aa7acbda4/"}]}}, {"id": "source:053419f368676f2469ea023f4e0a3e1b2e945ed3c1994c5c34801aa4bc954f69", "url": "https://finance.yahoo.com/markets/stocks/articles/abbott-laboratories-abt-could-10-161147968.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/abbott-laboratories-abt-could-10-161147968.html", "title": "Abbott Laboratories (ABT) Could Be 10% Undervalued On Its $1.35b Buyback Update", "content_text": "Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Abbott Laboratories buyback update Abbott Laboratories (ABT) has completed a share repurchase tranche that saw the company buy back 14,015,097 shares for about US$1.35b, including 11,599,094 shares between April and June 2026. See our latest analysis for Abbott Laboratories. Abbott Laboratories shares trade at US$107.81 and have gained 27.86% over the past 90 days, while the year-to-date share price return is down 13.19% and the 1-year total shareholder re", "date_published": "2026-08-08T16:11:47+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Capital return", "ABL"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ABL", "name": "Abbott Laboratories", "sentiment_url": "https://sharemaestro.com/sentiment/5aee0440-2bab-4e30-b16e-000aa7acbda4/"}]}}, {"id": "source:754eb55fa616be18d7d9d6f68db0e6d4317e485ba2fd308186555c4b0d96516a", "url": "https://seekingalpha.com/news/4629566-insider-trades-microsoft-meta-pfizer-among-notable-names?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "external_url": "https://seekingalpha.com/news/4629566-insider-trades-microsoft-meta-pfizer-among-notable-names?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "title": "Insider trades: Microsoft, Meta, Pfizer among notable names", "content_text": "[Meta European head office] Derick Hudson Insider transactions were seen across major firms this week, including Microsoft (MSFT [https://seekingalpha.com/symbol/MSFT]) and Meta (META [https://seekingalpha.com/symbol/META]). The following trades took place between August 3 and August 7. * Microsoft (MSFT [https://seekingalpha.com/symbol/MSFT]) saw two executives divest a small part of their positions in the company this week. EVP and Chief Marketing Officer Takeshi Numoto sold 4,810 shares at $496.48 each for ~$2.39M. The transaction represented about 10.13% of his direct holdings, leaving him", "date_published": "2026-08-08T15:03:14+00:00", "authors": [{"name": "seekingalpha.com"}], "tags": ["Market update", "BSX"], "_sharemaestro": {"country": "Germany", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "BSX", "name": "Boston Scientific Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/e71a4929-5366-46c6-b81d-15099a7fb8e0/"}]}}, {"id": "source:d29e64cddcab6913d36375e70ae7b02d3ae5d719e56dd0dd9c119f7db559852e", "url": "https://news.google.com/rss/articles/CBMiYkFVX3lxTE55b3Nkb05ZRHlNcFY4RF9ZWGJ4VHhXMjkycjNERWlkODBtbUo5SWJvenpnVk1YSWEwOEFGcl9uVWhWVlFzdTZLOWNtRUtodzdqTkFtMGdxLUk3NDFBeXdZbGlB?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiYkFVX3lxTE55b3Nkb05ZRHlNcFY4RF9ZWGJ4VHhXMjkycjNERWlkODBtbUo5SWJvenpnVk1YSWEwOEFGcl9uVWhWVlFzdTZLOWNtRUtodzdqTkFtMGdxLUk3NDFBeXdZbGlB?oc=5", "title": "Edwards Lifesciences Corp (EW) Aktuelle Aktien-News", "content_text": "Edwards Lifesciences Corp (EW) Aktuelle Aktien-News", "date_published": "2026-08-07T22:09:49+00:00", "authors": [{"name": "TradingKey"}], "tags": ["Market update", "EWL"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "EWL", "name": "Edwards Lifesciences Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/d182ff67-5fcd-48c1-9450-8975babb5883/"}]}}, {"id": "source:0430c59c3e06fa7c605501d25add16896d0864a67a6c21fcdb18e4d186dc3014", "url": "https://finance.yahoo.com/healthcare/articles/boston-scientific-bsx-recalls-mean-190939502.html", "external_url": "https://finance.yahoo.com/healthcare/articles/boston-scientific-bsx-recalls-mean-190939502.html", "title": "What Do Boston Scientific (BSX) Recalls Mean For Device Safety And Clinical Use?", "content_text": "Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Boston Scientific (NYSE: BSX) has initiated multiple product recalls covering cardiac ablation generators and vascular access sheaths due to labeling discrepancies and air embolism risks. The recalls affect a broad mix of devices used in cardiac and vascular procedures across several international markets. Regulators and hospitals are assessing the implications for device safety protocols, clinical workflows, and future use of the impacted products. Produc", "date_published": "2026-08-07T19:09:39+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Regulatory and legal", "BSX"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "BSX", "name": "Boston Scientific Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/e71a4929-5366-46c6-b81d-15099a7fb8e0/"}]}}, {"id": "source:c1ea3318e73bf6cc8885b946ac15195d129dda7dd9933cd8e35800e80461d1fd", "url": "https://news.google.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?oc=5", "external_url": "https://news.google.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?oc=5", "title": "Die Boston Scientific Corporation (NYSE:BSX) hat soeben ihre Ergebnisse ver\u00f6ffentlicht, und Analysten haben ein Kursziel von 62,69 US-Dollar festgelegt.", "content_text": "Die Boston Scientific Corporation (NYSE:BSX) hat soeben ihre Ergebnisse ver\u00f6ffentlicht, und Analysten haben ein Kursziel von 62,69 US-Dollar festgelegt.", "date_published": "2026-08-07T11:18:24+00:00", "authors": [{"name": "simplywall.st"}], "tags": ["Market update", "BSX"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "BSX", "name": "Boston Scientific Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/e71a4929-5366-46c6-b81d-15099a7fb8e0/"}]}}, {"id": "source:f6ba85f5c1e4eb97f710c4fde2f6f9e2d0c7bd5ae28478fb61c958e8f4e50c1d", "url": "https://news.google.com/rss/articles/CBMiY0FVX3lxTFBYQkN4LVlvb2VNcTNQT2ZHZEZBcEJYb1NkeUlXYjJ0My1QaFVrMlZIUmtKZ2xlcEljdU9oelhFWEtrMkppMXRUUGdaUWhDMUdzMGNjbXFybzl6eElmQ2hEMUlnTQ?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiY0FVX3lxTFBYQkN4LVlvb2VNcTNQT2ZHZEZBcEJYb1NkeUlXYjJ0My1QaFVrMlZIUmtKZ2xlcEljdU9oelhFWEtrMkppMXRUUGdaUWhDMUdzMGNjbXFybzl6eElmQ2hEMUlnTQ?oc=5", "title": "Koninklijke Philips NV (PHG) Aktuelle Aktien-News", "content_text": "Koninklijke Philips NV (PHG) Aktuelle Aktien-News", "date_published": "2026-08-07T09:57:21+00:00", "authors": [{"name": "TradingKey"}], "tags": ["Market update", "PHI1"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "PHI1", "name": "Koninklijke Philips N.V.", "sentiment_url": "https://sharemaestro.com/sentiment/1cc4de78-0344-4bf2-8f9e-a385142353b4/"}]}}, {"id": "source:0956fc3ed13a9a05b4941dd192ec23f08574b363c283b8e12f6e59085854cb91", "url": "https://news.google.com/rss/articles/CBMiaEFVX3lxTFA1YU9zREV1am1XbjlaMVJiT1hYRE41RTlzS1VoMmZfeTNQeUc3aUN2aGdIR25VMnRjZTUtTThBZi1CMl9RZF9DQlVPNThKSEl3YTNqQXNDN3gzaTRzblZJajRCVnZXTnd5?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiaEFVX3lxTFA1YU9zREV1am1XbjlaMVJiT1hYRE41RTlzS1VoMmZfeTNQeUc3aUN2aGdIR25VMnRjZTUtTThBZi1CMl9RZF9DQlVPNThKSEl3YTNqQXNDN3gzaTRzblZJajRCVnZXTnd5?oc=5", "title": "Boston Scientific Corp (BSX) Gewinnprognose: Zuk\u00fcnftige EPS & Umsatzwachstumsprognosen", "content_text": "Boston Scientific Corp (BSX) Gewinnprognose: Zuk\u00fcnftige EPS & Umsatzwachstumsprognosen", "date_published": "2026-08-07T07:00:00+00:00", "authors": [{"name": "TradingKey"}], "tags": ["Earnings", "BSX"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "BSX", "name": "Boston Scientific Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/e71a4929-5366-46c6-b81d-15099a7fb8e0/"}]}}, {"id": "source:d794e85051df34496b06ec460742d6c77129b66f341eaeab4fa8e31a6d63e3fe", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxOZnBhUXJHRUxuYlgzSFJLYllVUEtxV2t0cUJadVMtXzRFcldYa3F3SGRRWWFBUDdJVTFYTG1Xc21faE03NWI4ajF1V0p5S3p4elJNc0lPWWdmRkFYcndMYnpJS0hrSUtiQzRQSVcwYVY5dkdmM3hfdmhKMDEyVjlpYVg5VTVPSE55TkFlN3dQM2w?oc=5", "external_url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxOZnBhUXJHRUxuYlgzSFJLYllVUEtxV2t0cUJadVMtXzRFcldYa3F3SGRRWWFBUDdJVTFYTG1Xc21faE03NWI4ajF1V0p5S3p4elJNc0lPWWdmRkFYcndMYnpJS0hrSUtiQzRQSVcwYVY5dkdmM3hfdmhKMDEyVjlpYVg5VTVPSE55TkFlN3dQM2w?oc=5", "title": "Eckert & Ziegler SE: Konsensus der Analysten und Kursziel | 565970 | DE0005659700", "content_text": "Eckert & Ziegler SE: Konsensus der Analysten und Kursziel | 565970 | DE0005659700", "date_published": "2026-08-07T07:00:00+00:00", "authors": [{"name": "MarketScreener Deutschland"}], "tags": ["Market update", "EUZ"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "EUZ", "name": "Eckert & Ziegler SE", "sentiment_url": "https://sharemaestro.com/sentiment/451afbcd-39e0-41f6-816d-ddcebe221c0c/"}]}}, {"id": "source:404ab4e004b51358db984474e95b2146403716f3601d177f5665819dfc2195df", "url": "https://news.google.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?oc=5", "external_url": "https://news.google.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?oc=5", "title": "Die angehobene Umsatzprognose f\u00fcr das Portfolio im Bereich der strukturellen Herzerkrankungen f\u00fcr 2026 k\u00f6nnte f\u00fcr Edwards Lifesciences (EW) eine entscheidende Wende bedeuten", "content_text": "Die angehobene Umsatzprognose f\u00fcr das Portfolio im Bereich der strukturellen Herzerkrankungen f\u00fcr 2026 k\u00f6nnte f\u00fcr Edwards Lifesciences (EW) eine entscheidende Wende bedeuten", "date_published": "2026-08-06T07:00:00+00:00", "authors": [{"name": "simplywall.st"}], "tags": ["Market update", "EWL"], "_sharemaestro": {"country": "Germany", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "EWL", "name": "Edwards Lifesciences Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/d182ff67-5fcd-48c1-9450-8975babb5883/"}]}}]}